Cabiralizumab + Nivolumab in Advanced Solid Tumors

Phase 1, open-label trial of cabiralizumab in solid tumor (advanced stage), head and neck cancer (HNC), pancreatic cancer (PC) and 6 more (3 arms), sponsored by Five Prime Therapeutics, Inc. Primary endpoints: Number of Participants With Grade 3 or Grade 4 Adverse Events and Laboratory Abnormalities Defined as Dose Limiting Toxicities at 28 days, Recommended Dose of Cabiralizumab in Combination With Nivolumab at 28 days and 3 more. Started Sep 2015; status: completed.